Authors
Latest:
What are considerations when selecting a neuromodulation technique for OAB?"There are actually no data to support that 1 neuromodulation is better than another based on disease severity, and this is based on the systematic review done for the OAB guideline," says Anne Pelletier Cameron, MD, FRCSC, FPMRS.
Latest:
Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC“[These are] very good numbers for these patients who otherwise would undergo a radical cystectomy," says Félix Guerrero-Ramos, MD, PhD, FEBU.
Latest:
Mayo study finds dietary habits that may help prevent kidney stones"Knowing the dietary factors that are most important for preventing kidney stone recurrence can help patients and providers know what to prioritize,” said Andrew Rule, MD.
Latest:
Amir Patel, MD, on onabotulinumtoxinA injection at the time of HoLEPAmir S. Patel, MD, discusses interim findings from a randomized controlled trial of onabotulinumtoxinA injection at the time of HoLEP vs standard treatment.
Latest:
Shared Decision-Making and Treatment AdherencePanelists discuss how shared decision-making allows patients to test-drive oral androgen deprivation therapy options, providing flexibility for those concerned about quality-of-life impact or performance status, enabling them to start or stop treatment as needed.
Latest:
Survey highlights communication gaps with kidney cancer diagnosis and care“This indicates opportunities to improve communication about diagnosis, psychosocial impacts, and clinical trials, as well as biopsies, physical exercise, and patient engagement,” wrote Rachel H. Giles, PhD, and colleagues.
Latest:
Future of BCG in NMIBCPanelists discuss how it would be preferred that BCG monotherapy not remain the first-line treatment for intermediate-risk and high-risk disease within the next 10 years. It is encouraged that the future of first-line treatment be a noninfectious agent that would be easier to develop and include more data.
Latest:
Paul Sieber, MD, on the future of genetic testing in prostate cancerSieber shares his thoughts on the potential for universal genetic testing to become a standard of care practice for patients with prostate cancer.
Latest:
Selecting Between Receptor Pathway Inhibitors for mHSPCExplore the complexities of treatment options for metastatic hormone-sensitive prostate cancer, emphasizing shared decision-making and patient considerations.
Latest:
Shared Decision-Making and Treatment AdherencePanelists discuss how shared decision-making allows patients to test-drive oral androgen deprivation therapy options, providing flexibility for those concerned about quality-of-life impact or performance status, enabling them to start or stop treatment as needed.
Latest:
Howard Goldman, MD, on his experience with the Glean Urodynamics SystemHoward B. Goldman, MD, who was the first to use the device in a clinical setting, shares his initial thoughts on the technology and its role in real-world practice.
Latest:
Future Directions in PSMA-PET ImagingLooking to the future treatment landscape in prostate cancer, the panel provides closing thoughts on the trajectory of the utilization of PSMA-PET imaging and the unmet needs it might address.
Latest:
Experts consider efficacy of fertility restoration vs sperm cryopreservation“While I would hesitate to say that reversal is truly better in terms of efficacy, I think this data suggests that it's at least as good,” says Scott D. Lundy, MD, PhD, HCLD.
Latest:
Financial toxicity is a growing concern in urologic oncology"Clinicians have opportunities to reduce patient subjective and objective financial burden if they continue to self-educate and communicate with patients and consider [financial toxicitiy] an adverse effect of treatment," write Alexandria A. Spellman, MD, MS, and Deborah R. Kaye, MD, MS.
Latest:
Naeem Bhojani, MD, expands on key findings from WATER III trial“I think it will help patients decide what prostate surgery they want,” says Naeem Bhojani, MD, FRCSC.
Latest:
Future Directions in PSMA-PET ImagingLooking to the future treatment landscape in prostate cancer, the panel provides closing thoughts on the trajectory of the utilization of PSMA-PET imaging and the unmet needs it might address.
Latest:
13 tips to keep your patient data safe from hackersHere are 13 cybersecurity measures medical practices can take to protect patient data from hackers.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Practice Management: Expert coding tipsA physician’s goal is to care for patients, but a key part of being able to provide that care is the eternal quest for payment.
Latest:
Sarah Razavi, MD, outlines strategies for mitigate surgeon discomfort during URSOne crucial recommendation is incorporating an ergonomic training module into the curriculum.
Latest:
Post-RP incontinence: Low procedure rates examinedThe findings strongly support a proactive approach to identifying and referring patients with poor urinary function after RP.
Latest:
Gopa Iyer, MD, highlights SURF301 trial of TYRA-300 in mUC"The preliminary results of that study, which is a phase 1/2 dose escalation and dose expansion trial, were presented by Professor Ben Tran last year at the ENA meeting1 and showed a very favorable toxicity profile compared to erdafitinib," says Gopa Iyer, MD.
Latest:
RX Review: Implementing mitomycin for LG-IR-NMIBC in clinical practiceIn this video, part 5 in a 5-part series, panelists examine the economic and logistical realities of bringing mitomycin for intravesical solution (Zusduri; formerly UGN-102) into private practice.
Latest:
Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer TreatmentJack R. Andrews, MD; Eugene B. Cone MD; and Edwin Posadas, MD, FACP, discuss how early intervention with individualized treatment approaches based on disease volume, patient characteristics, and biomarkers significantly improves survival outcomes in metastatic hormone-sensitive prostate cancer.
Latest:
Pearls & Perspectives: Premature ejaculation, with Brian L. Steixner, MDHost Amy Pearlman, MD, discusses premature ejaculation with Brian L. Steixner, MD, a board-certified urologist in Linwood, New Jersey.
Latest:
Jason Scovell, MD, on clinical utility of IsoPSA across racial groupsThe test demonstrated comparable or superior performance in Black and Non-White men.
Latest:
Vaginal prolapse repair and sling surgery significantly reduce UUI"The biggest message from this study is that 60% can expect resolution of UUI, simply by fixing the prolapse and placing a sling, which is not normally indicated for UUI," according to Christina M. Mezes, DO, and Catherine A. Matthews, MD.
Latest:
Managing BCG-Unresponsive NMIBC: Cretostimogene Monotherapy vs. Combination TherapyPanelists discuss their views on using cretostimogene as monotherapy versus combination therapy, the importance for urologists to stay updated on advances for managing BCG-unresponsive NMIBC, and the potential impact of combining cretostimogene with pembrolizumab on addressing unmet needs in NMIBC care.
Latest:
Upper tract urothelial carcinoma case illustrates rapidly changing treatment landscapeUrologists and medical oncologists should collaborate to tailor therapy to the specific needs of the patient.
Latest:
Management of recurrent prostate cancer after focal therapyProviders must carefully consider treatment options to align with patient preference.
